Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants
A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Ointment for the Treatment of HIV-negative Patients With Anal High-grade Squamous Intraepithelial Lesions (Anal HSIL)
Frantz Viral Therapeutics, LLC
48 participants
Jan 12, 2024
INTERVENTIONAL
Summary
This is a phase II double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Four 5-day cycles of artesunate ointment given at weeks 0, 2, 4, 6
Four 5-day cycles of placebo ointment given at weeks 0, 2, 4, 6
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06206564